Veterinary Vaccines Market Share, Trends, Demand And Business Challenges 2022-2030

Veterinary Vaccines Market – By Technology, By Application, By Disease Type- Regional Outlook, Competitive Strategies and Segment Forecast to 2030

Veterinary Vaccines Market – By Technology, By Application, By Disease Type- Regional Outlook, Competitive Strategies and Segment Forecast to 2030

Published: Aug 2022 Report ID: PHAR2206 Pages: 1 - 245 Formats*:     
Category : Pharmaceutical
Global Veterinary Vaccines Market Overview:

According to SPER Market Research, the Global Veterinary Vaccines Market is estimated to reach USD 14.58 billion by 2030 with a CAGR of 6.9%. Veterinary vaccines are substances that are given to animals in order to increase the production of antibodies and give them immunity from one or more diseases. Branded veterinary vaccines include Inforce3®, which is given to healthy cattle, including pregnant cows, to help prevent respiratory diseases brought on by the infectious bovine rhinotracheitis (IBR) virus, parainfluenza 3 (PI3) virus, and the bovine respiratory syncytial virus (BRSV).

Growth over the historical era was driven by the expansion of new markets, rising expenditure on pets, rising illness prevalence, rising outbreaks of poultry diseases, and increasing zoonotic disease incidence. The lack of veterinarians, ignorance, high costs associated with animal care and storage, an increase in the supply of fake vaccinations, and strict laws all had a detrimental impact on growth during that time.

The market for veterinary vaccines is anticipated to see growth restrictions due to the concentration of clients and distributors. Recent years have seen a growth in the number of veterinarians working in big clinics and hospitals, as well as the consolidation of distributors of veterinary supplies and animal producers, notably of swine and poultry. 

As a replacement for veterinary medicines to combat antibiotic resistance, nanotechnology is gaining ground in the market for veterinary vaccinations. Controlling matter at the atomic and molecular levels is the subject of nanotechnology research. The manufacture, stimulation of animal development, diagnosis, and treatment of veterinary vaccinations are all improved by the application of nanotechnology. In order to use less antibiotics and better identify harmful microorganisms, nanoparticles are mostly employed as substitute antimicrobial agents. In order to enhance the qualities and performance of new drugs and vaccine candidates as well as to lower animal organism drug resistance, they are also used as drug delivery agents..

Impact of COVID-19 on the Veterinary Vaccines Market
Demand for veterinary vaccination has increased significantly as a result of the recent COVID-19 epidemic. Veterinarian clinics all around the world have made substantial changes to ensure that livestock and animals receive the essential veterinary treatment and that new safety measures are in place to protect both animals and veterinarians.

Scope of the report:
 Report Metric Details
 Market size available for years 2019-2030
 Base year considered 2021
 Forecast period 2022-2030
 Segments coveredBy Technology, By Application, By Disease Type , By  Region
 Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
 Companies Covered
Animalcare, Agrovet Market Animal Health , BASF India Ltd., Bayer, Animal Health Cadila Vaccines Ltd., Bimeda, Boehringer Ingelheim GmbH, Ceva Santé Animale, Century Vaccines Limited,Chemo Argentina, DBK Pharma S.A.E., Elanco Animal Health Incorporated, HIPRA, IDT Biologika, Interfeed, Jurox Pty Ltd, Kyoritsu Seiyaku Corporation, Merck Animal Health, MSD Animal Health, Nimrod Veterinary Products Ltd., Novartis Animal Health, Phibro Animal Health Corporation, Sanofi Animal Health Inc., UCBVET, Virbac RSA, Zoetis India

Veterinary Vaccines Market Segmentation:

By Technology: Based on the Technology, Veterinary Vaccines Market is segmented as; Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines , Recombinant Vaccines, Other Vaccines.

By Application: Based on the Application, Veterinary Vaccines Market is segmented as; Livestock Vaccines, Companion Animal Vaccines.
By Disease Type: Based on the Disease Type, Veterinary Vaccines Market is segmented as; Anaplasmosis, Canine Parvovirus, Foot & Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, Porcine Reproductive & Respiratory Syndrome (PRRS),  Others

By Region: The Veterinary Vaccines market is majorly driven by Asia Pacific. During the projected period, Asia Pacific is anticipated to have the quickest rate of growth in the worldwide Veterinary Vaccines market. 

1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Veterinary Vaccines Market

5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Veterinary Vaccines Market, By Technology, 2019-2030 (USD Million)
6.1. Live Attenuated Vaccines
6.2. Inactivated Vaccines
6.3. Toxoid Vaccines
6.4. Recombinant Vaccines
6.5. Other Vaccines

7. Veterinary Vaccines Market, By Application, 2019-2030 (USD Million)
7.1. Livestock Vaccines
7.2. Companion Animal Vaccines

8. Veterinary Vaccines Market, By Disease Type, 2019-2030 (USD Million)
8.1. Anaplasmosis
8.2. Canine Parvovirus
8.3. Foot & Mouth Disease
8.4. Newcastle Disease
8.5. Distemper Disease
8.6. Influenza
8.7. Porcine Reproductive & Respiratory Syndrome (PRRS)
8.8. Others

9. Veterinary Vaccines Market, By Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia 
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa

10. Company Profiles
10.1. Animalcare
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary 
10.1.4. Recent developments
10.2. Agrovet Market Animal Health
10.2.1. Company details 
10.2.2. Financial outlook
10.2.3. Product summary 
10.2.4. Recent developments
10.3. BASF India Ltd.
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Bayer Animal Health Cadila Vaccines Ltd.
10.4.1. Company details 
10.4.2. Financial outlook
10.4.3. Product summary 
10.4.4. Recent developments
10.5. Bimeda
10.5.1. Company details 
10.5.2. Financial outlook
10.5.3. Product summary 
10.5.4. Recent developments
10.6. Boehringer Ingelheim GmbH
10.6.1. Company details 
10.6.2. Financial outlook
10.6.3. Product summary 
10.6.4. Recent developments
10.7. Ceva Santé Animale
10.7.1. Company details 
10.7.2. Financial outlook
10.7.3. Product summary 
10.7.4. Recent developments
10.8. Century Vaccines Limited 
10.8.1. Company details 
10.8.2. Financial outlook
10.8.3. Product summary 
10.8.4. Recent developments
10.9. Chemo Argentina
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. DBK Pharma S.A.E.
10.10.1. Company details 
10.10.2. Financial outlook
10.10.3. Product summary 
10.10.4. Recent developments
10.11. Elanco Animal Health Incorporated
10.11.1. Company details 
10.11.2. Financial outlook
10.11.3. Product summary 
10.11.4. Recent developments
10.12. HIPRA
10.12.1. Company details 
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. IDT Biologika
10.13.1. Company details 
10.13.2. Financial outlook
10.13.3. Product summary 
10.13.4. Recent developments
10.14. Interfeed 
10.14.1. Company details 
10.14.2. Financial outlook
10.14.3. Product summary 
10.14.4. Recent developments
10.15. Jurox Pty Ltd
10.15.1. Company details 
10.15.2. Financial outlook
10.15.3. Product summary 
10.15.4. Recent development
10.16. Kyoritsu Seiyaku Corporation
10.16.1. Company details 
10.16.2. Financial outlook
10.16.3. Product summary 
10.16.4. Recent developments
10.17. Merck Animal Health
10.17.1. Company details 
10.17.2. Financial outlook
10.17.3. Product summary 
10.17.4. Recent developments
10.18. MSD Animal Health
10.18.1. Company details 
10.18.2. Financial outlook
10.18.3. Product summary 
10.18.4. Recent developments
10.19. Nimrod Veterinary Products Ltd.
10.19.1. Company details 
10.19.2. Financial outlook
10.19.3. Product summary 
10.19.4. Recent developments
10.20. Novartis Animal Health
10.20.1. Company details 
10.20.2. Financial outlook
10.20.3. Product summary 
10.20.4. Recent developments
10.21. Phibro Animal Health Corporation
10.21.1. Company details 
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments
10.22. Sanofi Animal Health Inc.
10.22.1. Company details 
10.22.2. Financial outlook
10.22.3. Product summary
10.22.4. Recent developments
10.23. UCBVET
10.23.1. Company details 
10.23.2. Financial outlook
10.23.3. Product summary
10.23.4. Recent developments
10.24. Virbac RSA
10.24.1. Company details 
10.24.2. Financial outlook
10.24.3. Product summary 
10.24.4. Recent developments
10.25. Zoetis India
10.25.1. Company details 
10.25.2. Financial outlook
10.25.3. Product summary 
10.25.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.




Not able to find what you are looking for? Need customization in the existing report?
Click Here
  • 15% off
    $ 4250
  • 20% off
    $ 5650
  • 25% off
    $ 7450
Pre-Purchase Inquiry
Request Customization
100% Secure Payment

SPER American Express
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Johnson & Johnson
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Johnson & Johnson


Market Research

We are the leading, full-service global market research and consulting company.

iso-1 iso-1 iso-1 ESOMAR
Secure Payments
SPER Payment Options
Contact HR

 [email protected]